Malignant Mesothelioma malady

Disease Ontology: A cell type cancer that has material basis in meothelial tissue.⁶

MalaCards: Malignant Mesothelioma, also known as advanced malignant mesothelioma, is related to benign mesothelioma and malignant pleural mesothelioma. An important gene associated with Malignant Mesothelioma is MMS (Malignant mesothelioma, susceptibility to), and among its related pathways are Apoptosis and Autophagy and Actin-Based Motility by Rho Family GTPases. The drug doxorubicin hydrochloride and the compounds lysine and glycogen have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and thyroid, and related mouse phenotypes are respiratory system and craniofacial.

Aliases & Descriptions:

malignant mesothelioma 6 30 8 33 32 43 advanced malignant mesothelioma 6 43 diffuse malignant mesothelioma 6 43 mesothelioma, malignant (morphologic abnormality) 6 asbestos-related malignant mesothelioma 6

malignant tumor of mesothelium 6 mesothelioma diffuse malignant 32 mesothelioma, malignant 30 malignant neoplasms 43 mesothelioma 43

Diseases related to malignant mesothelioma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1171)

id	Related Disease	Score	Top Affiliating Genes
1	benign mesothelioma	37.3	VIM, MYOG, MYOD1, BCL10, BCL2L1, MUC1
2	malignant pleural mesothelioma	35.9	SFTPB, BIRC5, BCL2L1, MUC1, MUC16, MTAP
3	tongue cancer	35.1	VEGFC, BCL2L1, CDKN1A, CDH1, MMP2, MMP9
4	malignant peritoneal mesothelioma	34.2	VIM, BIRC5, MUC1, MUC16, CALB2, EGFR
5	nasopharynx carcinoma	32.3	VEGFA, RASSF1, CDKN2A, CDH1, MMP9, CASP3
6	salivary gland cancer	31.9	KIT, BIRC5, CHUK, MMP9, MET, CASP3
7	neurofibromatosis	31.8	KIT, KITLG, MSH2, ENO2, NGFR, NF2
8	adenomatoid tumor	31.3	VIM, MUC1, CEACAM5, MMP2, CALB2, PTGER4
9	sarcomatoid mesothelioma	31.3	VIM, NAPSA, MUC1, S100A1, CEACAM3, CALB2
10	thyroid cancer	31.1	APC, TP63, CTNNA1, KRT20, KRT19, NKX2-1
11	oral cavity cancer	30.7	NAT2, VEGFA, PARP1, BAX, GSTM1, GSTT1
12	brain cancer	30.7	VEGFA, BAX, ENO2, PDGFRB, EGFR, TAG
13	malignant biphasic mesothelioma	30.4	MSLN, CALB2, WT1, THBD
14	stomach carcinoma	30.4	RASSF1, CHGA, CEACAM5, CDKN2A, CDH1, PLAU
15	ovarian cancer	30.2	MUC16, CEACAM3, CALB2, KRT7, KRAS, SLC2A1
16	thoracic cancer	30.2	KDR, MSLN, CDKN1A, CASP3, CASP8, CASP9
17	synovial sarcoma	30.0	KIT, VIM, RASSF1, BCL2, MUC1, CDH1
18	hepatitis	30.0	GPC3, IFNA2, IFNB1, TXN, HIC1, TIMP2
19	malignant peripheral nerve sheath tumor	29.8	KIT, VIM, MUC1, S100A1, CDKN2B, CDKN2A
20	bronchogenic carcinoma	29.4	CEACAM5, CEACAM7, CDKN1A, CDKN2A, IL10, IL2
21	anaplastic carcinoma	29.3	VIM, MUC1, CEACAM3, CDH1, FHIT, ENO2
22	cardia cancer	29.2	PARP1, XRCC1, CDKN2A, GSTM1, GSTT1, MDM2
23	thrombocytosis	29.1	KITLG, VEGFA, IL6, IFNA2, CALB2, PDGFRB
24	squamous cell carcinoma	29.0	CDH1, MMP10, DAPK1, CYP2D6, KRT19, EGF
25	pancreatic cancer	28.9	VEGFA, BIRC5, KDR, CHGA, MUC1, CEACAM5
26	thyroid cancer, follicular	28.9	VEGFC, KDR, FLT1, PLAU, KRT19, TYMS
27	kaposi's sarcoma	28.8	VEGFA, VEGFC, KDR, CD34, FLT4, FGF1
28	diffuse gastric cancer	28.7	XRCC3, CDH3, CDH1, GSTM1, GSTT1, ERCC2
29	multiple endocrine neoplasia	28.7	SF1, CHGA, CDKN1A, CDH2, CDKN2B, CDKN2A
30	asbestosis	28.5	VIM, MUC1, MSLN, CDKN1A, GSTM1, GSTT1
31	thymic carcinoma	28.4	KIT, VIM, VEGFC, BCL2, MUC1, S100A1
32	colorectal cancer	28.2	NAT2, CHEK2, MSH2, GSTM1, GSTT1, APC
33	pancreatic ductal carcinoma	28.1	PIK3CG, VEGFA, MUC1, MUC16, CEACAM7, MSLN
34	mixed cell type cancer	28.1	VIM, ENO2, TP53, KRT7, KRT20, KRT14
35	wilms tumor	28.1	NCAM1, PCNA, VIM, VEGFA, VEGFC, MYOG
36	urinary bladder cancer	27.9	RB1, NAT2, RASSF1, BIRC5, KDR, JUP
37	breast cancer	27.6	BMP6, CDK4, CDH1, ITGB4, AREG, APC
38	prostate carcinoma	27.5	NAT2, VEGFA, BMP6, PARP1, CDH1, MMP9
39	pulmonary blastoma	27.3	VIM, TP53, CTNNB1, KRAS, EGFR, SYP
40	familial colorectal cancer	27.1	BCL2, BCL2L1, CHEK2, MSH2, CDKN2A, CDH1
41	large cell carcinoma	27.0	BCL2, CHGA, BAX, CEACAM3, MCL1, ENO2
42	male breast cancer	26.8	PCNA, CHEK2, ESR1, ESR2, TP53, SP1
43	hodgkin's lymphoma	26.8	PIK3CG, BCL2, BCL2L1, CHUK, XIAP, IL18R1
44	acute lymphoblastic leukemia	26.7	KIT, KITLG, RB1, BCL2, BCL2L1, CHUK
45	cystadenocarcinoma	26.6	PCNA, VIM, VEGFA, BIRC5, BCL2, MUC1
46	hypoglycemia	26.6	PIK3CG, PCNA, VIM, VEGFA, CHGA, CDKN1C
47	small cell carcinoma	26.4	NCAM1, KIT, PCNA, RB1, VIM, VEGFA
48	thyroid cancer, anaplastic	26.3	BCL2L1, CDKN1A, CDH1, MET, MAPK1, IGF1R
49	liver cancer	26.3	PIK3CG, RB1, NAT2, VEGFA, BMP6, RASSF1
50	renal cell carcinoma	26.2	KIT, PCNA, VIM, NAPSA, VEGFA, VEGFC

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 doxorubicin hydrochloride

MalaCards organs/tissues related to malignant mesothelioma:

²²

MGI Mouse Phenotypes related to malignant mesothelioma:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	11.0	SEMA3A, MYOG, MYOD1, GREM1, TP63, PTGER4
2	craniofacial phenotype	MP:0005382	10.4	KIT, KITLG, CDKN1C, GREM1, MAPK8, GPC3
3	endocrine/exocrine gland phenotype	MP:0005379	10.3	SF1, ZBTB16, CDKN2B, CDH3, CDKN1C, IL2
4	embryogenesis phenotype	MP:0005380	10.2	KIT, GCLC, VIM, MYOG, MYBL2, BIRC5
5	normal phenotype	MP:0002873	9.9	GCLC, BTC, VEGFA, MYOG, MYBL2, MYOD1
6	other phenotype	MP:0005395	9.7	KDR, CDKN2A, ITGA6, MME, MMP14, IL2
7	hematopoietic system phenotype	MP:0005397	9.2	KIT, PCNA, BCL10, BCL2, BCL2L1, BCL2L11
8	renal/urinary system phenotype	MP:0005367	8.9	KIT, BCL2, BCL2L11, UPK3A, CHGA, CHUK
9	hearing/vestibular/ear phenotype	MP:0005377	8.8	KIT, KITLG, RB1, BMP2, PARP1, BCL2
10	no phenotypic analysis	MP:0003012	8.7	PCNA, RB1, SEMA3A, VEGFA, VCAM1, MYBL2
11	nervous system phenotype	MP:0003631	8.6	KIT, KITLG, RB1, BMP2, PARP1, BCL10
12	pigmentation phenotype	MP:0001186	8.6	KIT, KITLG, RB1, BCL2, BCL2L11, CDKN2A
13	immune system phenotype	MP:0005387	8.4	KIT, SEMA3A, SEMA6D, VIM, KDR, BCL2L11
14	liver/biliary system phenotype	MP:0005370	8.4	KIT, GCLC, VEGFA, MTAP, MET, IL2
15	reproductive system phenotype	MP:0005389	8.2	SF1, VEGFA, MYOD1, BMP2, ZEB2, ZBTB16
16	limbs/digits/tail phenotype	MP:0005371	8.1	KIT, KITLG, RB1, VEGFA, BMP2, BCL2L11
17	mortality/aging	MP:0010768	7.8	NCAM1, KITLG, SF1, SFTPB, GCLC, GCLM
18	integument phenotype	MP:0010771	7.2	PIK3CG, KIT, KITLG, RB1, MYOG, PARP1
19	skeleton phenotype	MP:0005390	7.1	PIK3CG, KIT, KITLG, BTC, RB1, SEMA3A
20	behavior/neurological phenotype	MP:0005386	7.1	NCAM1, KIT, SFTPB, RB1, SEMA3A, VIM
21	adipose tissue phenotype	MP:0005375	7.1	RB1, MYOG, MYOD1, BCL2, MTOR, CDKN1A
22	digestive/alimentary phenotype	MP:0005381	6.7	KIT, KITLG, RB1, VEGFA, BMP2, BCL2
23	growth/size phenotype	MP:0005378	6.6	PIK3CG, KIT, KITLG, GCLC, BTC, RB1
24	vision/eye phenotype	MP:0005391	6.3	NCAM1, KIT, KITLG, RB1, VIM, VEGFA
25	tumorigenesis	MP:0002006	6.1	KIT, KITLG, SF1, RB1, RASSF1, BCL2
26	muscle phenotype	MP:0005369	5.7	PIK3CG, KIT, BTC, RB1, VIM, VEGFA
27	cardiovascular system phenotype	MP:0005385	5.3	PIK3CG, KIT, KITLG, BTC, RB1, SEMA3A
28	cellular phenotype	MP:0005384	4.8	PIK3CG, NCAM1, KIT, KITLG, PCNA, GCLC
29	homeostasis/metabolism phenotype	MP:0005376	4.6	PIK3CG, KIT, KITLG, SF1, SFTPB, GCLM

Articles related to malignant mesothelioma:

(show top 50)    (show all 235)

id	Title	Authors	Year	Affiliating Genes
1	Two cases of pulmonary sarcomatoid carcinoma mimicki ng malignant mesothelioma (20163019)	Inomata M.... Tobe K.	2010	VIM, CALB2
2	Pleural malignant mesothelioma with osteoclast-like g iant cells. (20403048)	Itami H.... Sakuma T.	2010	CALB2, NKX2-1
3	Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. (19302997)	Grigoriu B.... Scherpereel A.	2009	MSLN
4	Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. (18064689)	Pu R.T.... Michael C.W.	2008	WT1, KRT5, TP63
5	Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. (18958493)	Dacic S.... Popper H.	2008	CDKN2A
6	Primary malignant mesothelioma developed in liver. (18705333)	Kim D.S.... Kim K.K.	2008	KRT5
7	Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. (18454162)	Creaney J.... Millward M.J.	2008	MUC1
8	Uroplakin is not a reliable immunohistochemical marker for malignant mesothelioma of the pleura. (18528285)	Butnor K.J.... Ordonez N.G.	2008	UPK3A
9	A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation (17541913)	Szczepulska-Wojcik E.... Roszkowski-Sliz K.	2007	VIM, MUC1, CALB2
10	Ras pathway activation in malignant mesothelioma. (17805054)	Patel M.R.... Kratzke R.A.	2007	KRAS, SIK2
11	Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. (17953743)	Belyanskaya L.L.... Stahel R.A.	2007	TNFRSF10B, TNFSF10, TNFRSF10A
12	Stathmin is overexpressed in malignant mesothelioma. (17352214)	Kim J.Y.... Jablons D.	2007	STMN1
13	Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. (17938269)	Abayasiriwardana K.S.... Broaddus V.C.	2007	BCL2L11
14	Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention. (17824789)	Achcar R.d.e. .O.... Jagirdar J.	2007	STAT3
15	Autocrine growth by granulocyte colony-stimulating factor in malignant mesothelioma. (17062276)	Nishimura M.... Shimada J.	2006	CSF3
16	Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. (16740034)	Butnor K.J.... Cagle P.T.	2006	MME
17	Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finnish and Italian populations. (16697254)	Neri M.... Garte S.	2006	CYP1A1, GSTT1, GSTM1
18	Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. (15639718)	Tsou J.A.... Laird-Offringa I.A.	2005	CDH1, ESR1, RASSF1
19	Hyaluronan synthase expression in pleural malignant mesotheliomas. (15731923)	Kanomata N.... Ochiai A.	2005	HAS3
20	Malignant mesothelioma. (16054941)	Robinson B.W.... Lake R.A.	2005	CDKN2A, NF2
21	Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. (15592515)	Suzuki M.... Gazdar A.F.	2005	TNFRSF10C, PYCARD, HIC1
22	A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP (15628770)	Hada M.... Kazuhiro M.	2004	FGF2, VEGFA
23	Preclinical evaluation of the nonsteroidal anti-infla mmatory agent celecoxib on malignant mesothelioma chemoprevention. (14961568)	Catalano A.... Procopio A.	2004	BCL2, CASP3, VEGFA
24	Reduced Fhit protein expression in human malignant mesothelioma. (14569398)	Pylkkanen L.... Husgafvel-Pursiainen K.	2004	FHIT
25	Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors. (15720796)	Liu Z.... Klominek J.	2004	EGFR, TGFA, TKT
26	Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. (14976533)	Trupiano J.K.... Levine E.A.	2004	CASP3, DES, CALB2
27	The effects of taurolidine, a novel antineoplastic ag ent, on human malignant mesothelioma. (15569998)	Nici L.... Calabresi P.	2004	ANXA5
28	The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. (12589646)	Illei P.B.... Zakowski M.F.	2003	CDKN2A
29	Cadherins, catenins and APC in pleural malignant mesothelioma. (14595746)	Abutaily A.S.... Roche W.R.	2003	CDH1, APC, CDH2
30	The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma. (11954027)	Hecht J.L.... Pinkus G.S.	2002	WT1
31	Localized malignant mesothelioma of the epithelial ty pe occurring as a primary hepatic neoplasm: a case report with review of the li terature. (12588419)	Imura J.... Fujimori T.	2002	CALB2
32	The role of gemcitabine in the treatment of malignant mesothelioma. (11836671)	Kindler H.L.... Van Meerbeeck J.P.	2002	VEGFA
33	Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. (12194995)	Abutaily A.S.... Roche W.R.	2002	CDH1, CDH2, THBD
34	Phase I study of intraperitoneal recombinant human interleukin 12 in patients with MA1llerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. (12473577)	Lenzi R.... Freedman R.S.	2002	VEGFA, IFNG, IL10
35	SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. (11572935)	Cacciotti P.... Gaudino G.	2001	MET, HGF
36	Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma. (10962437)	Kahlos K.... Kinnula V.L.	2000	SOD2
37	Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. (10849094)	Thirkettle I.... Warn R.M.	2000	CDH1, CDH2
38	Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. (10492020)	Syrokou A.... Karamanos N.K.	1999	THBD
39	Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. (10451704)	Cheng J.Q.... Testa J.R.	1999	NF2
40	Human malignant mesothelioma cell growth: activation of janus kinase 2 and signal transducer and activator of transcription 1alpha for inhibition by interferon-gamma. (9485044)	Buard A.... Jaurand M.C.	1998	STAT1
41	Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. (9537587)	Klominek J.... Hauzenberger D.	1998	MET, HGF
42	Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. (9274533)	Kumar-Singh S.... Van Marck E.	1997	CD34
43	Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma. (7603742)	Bethwaite P.B.... Thornton A.	1995	PCNA
44	Immunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens. (7534025)	Motoyama T.... Watanabe H.	1995	VIM, MUC1
45	Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis. (7611439)	Shetty S.... Idell S.	1995	PLAU, PLAUR
46	An autopsy case of malignant mesothelioma associated with asbestosis. (7834080)	Watanabe M.... Nagura H.	1994	VIM, MUC1
47	Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests. (8043983)	Sexl V.... Base W.	1994	PTPRC
48	Splicing of the platelet-derived-growth-factor A-chain mRNA in human malignant mesothelioma cell lines and regulation of its expression. (1396665)	Langerak A.W.... Versnel M.A.	1992	PDGFA
49	Malignant mesothelioma: cytologic diagnosis with hist ologic, immunohistochemical, and ultrastructural correlation. (1609156)	Leong A.S.... Mukherjee T.M.	1992	MUC1
50	Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. (1744800)	Delahaye M.... van der Kwast T.H.	1991	MUC1, CEACAM3

Genes related to malignant mesothelioma according to GeneCards:

(show top 50)    (show all 218)

id	Symbol	Description	Score	GeneCards Section Context
1	MMS	Malignant mesothelioma, susceptibility to	11.1	Aliases & Descriptions
2	CALB2	calbindin 2	11.0	Publications
3	MSLN	mesothelin	11.0	Publications
4	NKX2-1	NK2 homeobox 1	11.0	Publications
5	CEACAM3	carcinoembryonic antigen-related cell adhesion molecule 3	11.0	Publications
6	THBD	thrombomodulin	11.0	Publications
7	PDPN	podoplanin	11.0	Publications
8	WT1	Wilms tumor 1	11.0	Publications
9	SFTPB	surfactant protein B	11.0	Publications
10	MUC1	mucin 1, cell surface associated	11.0	Publications
11	TAG	tumor antigen gene	11.0	Publications
12	MUC16	mucin 16, cell surface associated	11.0	Publications
13	SPP1	secreted phosphoprotein 1	11.0	Publications
14	CTNNA1	catenin (cadherin-associated protein), alpha 1, 102kDa	11.0	Publications
15	CEACAM5	carcinoembryonic antigen-related cell adhesion molecule 5	11.0	Publications
16	CDH2	cadherin 2, type 1, N-cadherin (neuronal)	11.0	Publications
17	TXN	thioredoxin	11.0
18	MET	met proto-oncogene (hepatocyte growth factor receptor)	11.0	Publications
19	SOD2	superoxide dismutase 2, mitochondrial	11.0	Publications
20	BCL2L1	BCL2-like 1	11.0	Publications
21	TYMS	thymidylate synthetase	11.0
22	CD7	CD7 molecule	11.0
23	BCL10	B-cell CLL/lymphoma 10	11.0	Publications
24	PPP1R15A	protein phosphatase 1, regulatory subunit 15A	11.0
25	SNAI2	snail homolog 2 (Drosophila)	11.0	Publications
26	CEACAM7	carcinoembryonic antigen-related cell adhesion molecule 7	11.0	Publications
27	NF2	neurofibromin 2 (merlin)	11.0	Publications
28	TNFRSF10C	tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain	11.0	Publications
29	HPSE	heparanase	11.0	Publications
30	RASSF1	Ras association (RalGDS/AF-6) domain family member 1	11.0	Publications
31	SLC4A1	solute carrier family 4, anion exchanger, member 1 (erythrocyte membrane protein band 3, Diego blood group)	11.0	Publications
32	EIF2AK3	eukaryotic translation initiation factor 2-alpha kinase 3	11.0	Publications
33	RNASE1	ribonuclease, RNase A family, 1 (pancreatic)	11.0
34	AREG	amphiregulin	11.0	Publications
35	VIM	vimentin	11.0	Publications
36	PDGFA	platelet-derived growth factor alpha polypeptide	11.0	Publications
37	TNFRSF10B	tumor necrosis factor receptor superfamily, member 10b	11.0	Publications
38	MCL1	myeloid cell leukemia sequence 1 (BCL2-related)	11.0	Publications
39	FLT4	fms-related tyrosine kinase 4	11.0	Publications
40	XIAP	X-linked inhibitor of apoptosis	11.0	Publications
41	MTAP	methylthioadenosine phosphorylase	11.0
42	ITGB4	integrin, beta 4	11.0
43	JUP	junction plakoglobin	11.0	Publications
44	KRT7	keratin 7	11.0	Publications
45	KRT20	keratin 20	11.0	Publications
46	DES	desmin	11.0	Publications
47	NAT2	N-acetyltransferase 2 (arylamine N-acetyltransferase)	11.0	Publications
48	CDKN2B	cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)	11.0	Publications
49	ABCC2	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	11.0	Publications
50	GPC3	glypican 3	11.0	Publications

Pathways related to malignant mesothelioma according to GeneDecks:

(show top 50)    (show all 205)

id	Pathway	Score	Top Affiliating Genes
1	Apoptosis and Autophagy3	10.7	BIRC5, BIRC7, PARP1, BCL10, BCL2, BCL2L1
2	Actin-Based Motility by Rho Family GTPases36	10.7	BTC, SEMA3A, ITGA6, ITGB4, AREG, IL2
3	Glioma Invasiveness36	10.6	KITLG, BTC, SEMA3A, VEGFC, BMP2, BMP6
4	Colorectal cancer20	10.4	PIK3CG, MSH2, MAPK8, CASP9, TGFB2
5	CREB Pathway36	10.2	KIT, KITLG, BTC, SEMA3A, BMP2, BMP6
6	Breast Cancer Regulation by Stathmin136	10.1	BTC, SEMA3A, BMP2, FGF1, FGF2, CCNH
7	Paxillin Interactions36	9.9	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
8	Apoptosis Signaling Pathways37	9.9	BIRC5, BIRC7, BCL2, BCL2L1, BAX, XIAP
9	ERK5 Signaling36	9.5	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
10	Epithelial Adherens Junctions36	9.4	KITLG, BTC, SEMA3A, VEGFC, BMP2, BMP6
11	ILK Signaling36	9.4	KIT, KITLG, BTC, SEMA3A, VIM, VEGFC
12	Apoptosis through Death Receptors36	9.4	BCL2, CHUK, BAX, MAPK8, CASP3, CASP8
13	NF-KappaB Family Pathway36	9.3	KITLG, BTC, SEMA3A, VEGFC, BMP2, BMP6
14	Akt Signaling36	9.3	PIK3CG, KIT, BTC, SEMA3A, VEGFC, BMP2
15	NF-KappaB (p50-p65) Pathway36	9.3	KITLG, BTC, SEMA3A, VEGFC, BMP2, BMP6
16	Telomerase Components in Cell Signaling36	9.2	KIT, KITLG, BTC, RB1, SEMA3A, VEGFC
17	eNOS Signaling36	9.2	KIT, KITLG, BTC, SEMA3A, BMP2, BMP6
18	JNK Pathway36	9.1	KIT, KITLG, BTC, BMP2, BMP6, KDR
19	Activation of cAMP-Dependent PKA36	9.1	KITLG, BTC, SEMA3A, VEGFC, BMP2, KDR
20	Rac1 Pathway36	9.0	KITLG, BTC, SEMA3A, BMP6, KDR, ITGA6
21	Nuclear Receptor Activation by Vitamin-A36	9.0	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
22	Intracellular Calcium Signaling36	8.9	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
23	PPAR Pathway36	8.8	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
24	mTOR Pathway36	8.7	KITLG, BTC, SEMA3A, VEGFC, BMP2, BMP6
25	eIF2 Pathway36	8.7	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP6
26	DHA Signaling36	8.6	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
27	cAMP Pathway36	8.4	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
28	GPCR Pathway36	8.3	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
29	NFAT in Immune Response36	8.3	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
30	Phospholipase-C Pathway36	8.3	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
31	p70S6K Signaling36	8.3	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
32	Cellular Apoptosis Pathway36	8.2	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
33	Mitochondrial Apoptosis36	8.1	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
34	Nanog in Mammalian ESC Pluripotency36	8.1	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
35	p53 Mediated Apoptosis36	8.1	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
36	Rap1 Pathway36	8.0	KITLG, BTC, SEMA3A, VEGFC, BMP2, BMP6
37	MAPK Signaling36	7.8	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
38	Tec Kinases Signaling36	7.7	KITLG, BTC, SEMA3A, VEGFC, BMP2, BMP6
39	Endothelin-1 Signaling Pathway36	7.6	KIT, BMP2, BMP6, FLT1, FLT4, IL10
40	TGF-Beta Pathway36	7.4	KITLG, BTC, SEMA3A, VEGFC, BMP2, BMP6
41	MAPK Family Pathway36	7.4	KITLG, BTC, SEMA3A, VEGFC, BMP2, BMP6
42	Estrogen Pathway36	7.3	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
43	Pancreatic Adenocarcinoma36	7.2	KIT, KITLG, BTC, RB1, SEMA3A, VEGFC
44	STAT3 Pathway36	7.2	BMP2, BMP6, BCL2, BAX, CDKN1A, MET
45	Colorectal Cancer Metastasis36	7.1	BIRC5, BCL2L1, BAX, MSH2, CDKN1A, CDH1
46	Bladder cancer20	7.0	RB1, VEGFA, VEGFC, RASSF1, CDKN1A, CDKN2A
47	ERK Signaling36	6.9	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
48	Rho Family GTPases36	6.8	KIT, KITLG, BTC, SEMA3A, VIM, VEGFC
49	Antioxidant Action of Vitamin-C36	6.5	KIT, KITLG, BTC, SEMA3A, VEGFC, BMP2
50	Pathways in cancer20	6.5	PIK3CG, RB1, VEGFA, VEGFC, BMP2, RASSF1

Compounds related to malignant mesothelioma according to GeneDecks:

(show top 50)    (show all 475)

id	Compound	Score	Top Affiliating Genes
1	lysine32	11.0	MYOD1, CHUK, MME, TP63, PLAU, RNASE1
2	glycogen32 18	11.5	PIK3CG, KIT, VIM, CHGA, CHUK, MUC1
3	agar32	10.5	KITLG, RB1, VIM, RASSF1, BIRC5, MUC1
4	arginine32	10.4	SFTPB, MYOD1, BMP2, CHGA, XRCC1, CDK4
5	atp32	10.4	NCAM1, KIT, SF1, SFTPB, RB1, MYOD1
6	h2o232	10.4	PIK3CG, KITLG, BCL2L11, CHEK1, MUC16, MME
7	vitamin a32 9 18 9	13.3	SFTPB, RB1, VIM, NAT2, BIRC5, MME
8	glyceraldehyde 3-phosphate32	10.3	VEGFC, MYOG, BIRC5, CEACAM5, MMP1, MMP14
9	cholesterol32 9 18 9	13.2	KITLG, SFTPB, RB1, NAT2, VCAM1, BMP2
10	tunicamycin32	10.2	PIK3CG, MAPK8, IGF1R, HSP90B1, CASP3, CASP8
11	dopamine32 9 18 9	13.1	NCAM1, BMP2, BMP6, CDKN2A, MME, MMP9
12	melphalan32 9 9	12.0	GCLC, BIRC5, BCL2L1, BCL2L11, MVP, MUC16
13	su541632	9.9	KIT, KITLG, VEGFA, BIRC5, KDR, FLT1
14	ceramide32	9.9	RB1, BCL2L1, BCL2L11, XIAP, CDK4, IL18R1
15	epinephrine32 9 18 9	12.9	KITLG, BMP6, CHGA, MVP, MMP1, MMP2
16	nmda32 42	10.8	NCAM1, VIM, BCL2L1, XIAP, CDH2, FGF1
17	p00232	9.7	KIT, RB1, BIRC5, CHGA, MVP, XRCC1
18	ascorbic acid32 18	10.5	PIK3CG, SFTPB, PCNA, MYOG, BMP2, CHUK
19	ribonucleic acid32	9.5	KIT, KITLG, SFTPB, VEGFC, MYOG, BMP2
20	alanine32	9.4	NCAM1, KITLG, PCNA, VCAM1, MYOD1, BMP2
21	mitomycin c32	9.4	PCNA, RB1, VCAM1, BIRC5, MVP, XRCC3
22	bleomycin32 9 9	11.3	SFTPB, MVP, XRCC1, GSTM1, FGF2, IFNB1
23	pge232	9.3	SFTPB, VCAM1, BMP2, CD86, CDH1, MME
24	glutamine32	9.2	PIK3CG, NCAM1, KIT, SF1, PCNA, VIM
25	glutamate32	9.0	NCAM1, PCNA, VIM, BMP6, KDR, CHUK
26	adenylate32	8.8	PIK3CG, KITLG, VIM, VCAM1, MYOG, CHGA
27	mitoxantrone32 9 9	10.8	BIRC5, BCL2, MVP, MTOR, ANXA5, IGF1R
28	cysteine32	8.7	SFTPB, PCNA, GCLC, NAT2, MYOG, PARP1
29	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide32	8.7	PCNA, PARP1, BCL2, BCL2L1, BAX, MMP2
30	etoposide32 42 9 9	11.6	PIK3CG, PCNA, RB1, BIRC5, PARP1, BCL2
31	indole-3-carbinol32	8.6	BIRC5, PARP1, BCL2, BCL2L1, BAX, XIAP
32	flavopiridol32 9 9	10.6	PIK3CG, KIT, RB1, VEGFA, BIRC5, PARP1
33	rottlerin32 42	9.5	PIK3CG, VCAM1, PARP1, XIAP, IL8, MCL1
34	temozolomide32 9 9	10.5	PCNA, VIM, VEGFA, PARP1, CHEK1, CHEK2
35	vinblastine32 9 9	10.4	VIM, BIRC5, KDR, BCL2, BCL2L1, MVP
36	simvastatin32 34 42 9 18 9	13.4	KITLG, VEGFA, VCAM1, BMP2, BMP6, KDR
37	rapamycin32 42	9.3	PIK3CG, KIT, KITLG, RB1, VIM, VEGFA
38	oxygen32 18	9.2	KITLG, SFTPB, RB1, MYOG, MYOD1, BMP2
39	superoxide32 18	9.0	KITLG, RB1, VCAM1, BIRC5, CHUK, XIAP
40	ag 147832	7.9	PIK3CG, BTC, MMP14, MMP2, MMP9, AREG
41	thapsigargin32 42	8.8	PIK3CG, PCNA, BCL2, BCL2L1, FGF1, IL2
42	lactate32	7.8	NCAM1, KIT, KITLG, PCNA, VIM, VCAM1
43	parthenolide32	7.8	PIK3CG, VCAM1, BCL2L1, CHUK, MMP9, IL6
44	prednisolone32 9 9	9.7	KITLG, VCAM1, BMP6, MVP, MMP1, MMP2
45	methotrexate32 34 42 9 9	11.6	KIT, KITLG, PCNA, RB1, VIM, NAT2
46	celecoxib32 42 34 9 18 9	12.6	PIK3CG, PCNA, VEGFA, BIRC5, PARP1, KDR
47	ciglitazone32	7.5	PARP1, BCL2L1, BAX, CDKN1A, MMP2, MMP9
48	sb 20358032 42	8.4	RB1, VIM, VEGFA, VCAM1, BMP2, BMP6
49	5fluorouracil32	5.6	PIK3CG, KIT, KITLG, PCNA, RB1, VEGFA
50	actinomycin d32	4.9	PIK3CG, KIT, KITLG, SFTPB, RB1, VIM

Cellular components related to malignant mesothelioma according to GeneDecks:

(show all 13)

id	Name	GO ID	Score	Top Affiliating Genes
1	integral to plasma membrane	GO:005887	10.6	PDGFRB, PDPN, ABCC1, ABCC2, ABCC3, ABCC5
2	catenin complex	GO:016342	10.6	CTNNB1, CTNNA1, CDH1, CDH2, JUP
3	cell-cell adherens junction	GO:005913	10.3	CTNNB1, APC, ITGA6, CDH1, CDH3, CDH2
4	cell surface	GO:009986	10.0	RPS6KB1, NGFR, PDGFA, TIMP2, THBD, TGFA
5	nucleolus	GO:005730	9.7	NF2, NOS3, PPP2R4, SP1, TP63, TP53
6	plasma membrane	GO:005886	8.7	PLAUR, PLXNA1, NOS3, NGFR, NF2, PDGFRB
7	nucleoplasm	GO:005654	8.7	SP1, TP63, TP53, TXN, ERCC2, ESR2
8	cytoplasm	GO:005737	8.7	PYCARD, DAPK1, SP1, CTNNB1, PPP2R4, SNAI2
9	membrane	GO:016020	8.6	ESR1, CTNNB1, NRP2, PDGFRB, EGFR, ABCC1
10	extracellular region	GO:005576	7.7	PLAUR, PLAU, SPP1, TNFSF10, TNFRSF1B, TXN
11	cytosol	GO:005829	7.7	PPP1R15A, CTNNB1, CTNNA1, CYCS, PYCARD, TP53
12	nucleus	GO:005634	7.3	TP53, TP63, CYCS, SP1, CTNNB1, PPP2R4
13	extracellular space	GO:005615	6.4	HGF, SPP1, TNXB, TNFSF10, IFNG, IFNB1

Biological processes related to malignant mesothelioma according to GeneDecks:

(show top 50)    (show all 54)

id	Name	GO ID	Score	Top Affiliating Genes
1	cell junction assembly	GO:034329	11.2	KRT14, KRT5, CTNNA1, FERMT2, ITGB4, ITGA6
2	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	10.9	EIF2AK3, BCL2L11, BAX, CDKN2A, IFNB1, CASP8
3	vascular endothelial growth factor receptor signaling pathway	GO:048010	10.8	PGF, PDGFRB, NRP2, FLT4, FLT1, KDR
4	odontogenesis of dentin-containing tooth	GO:042475	10.8	GATA6, NF2, CTNNA1, TP63, ITGA6, BAX
5	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	10.8	HGF, TGFB2, PDGFRB, PDGFA, CAT, FLT1
6	cellular response to mechanical stimulus	GO:071260	10.6	PTGER4, TNFRSF10B, TNFRSF10A, CASP8, MAPK8, CHEK1
7	cell adhesion	GO:007155	10.6	IL2, APC, TNXB, SPP1, CTNNA1, CTNNB1
8	male gonad development	GO:008584	10.5	GATA6, WT1, CTNNA1, MET, MSH2, BCL2L11
9	cell-cell junction organization	GO:045216	10.5	TGFB2, NF2, CTNNA1, CDH15, CDH1, CDH3
10	G1 phase of mitotic cell cycle	GO:000080	10.5	CCNH, CDK4, CDKN1C, CDKN2A, CDKN2B, CDKN1A
11	positive regulation of cell division	GO:051781	10.4	PGF, TGFB2, TGFA, PDGFA, CAT, APC
12	positive regulation of endothelial cell proliferation	GO:001938	10.4	PGF, NRP2, FGF2, FLT4, MTOR, KDR
13	peptidyl-tyrosine phosphorylation	GO:018108	10.4	CSF1R, SYK, EGF, PDGFRB, FLT4, FLT1
14	ovarian follicle development	GO:001541	10.4	CTNNA1, ESR2, BAX, BCL2L1, BCL2, KDR
15	replicative senescence	GO:090399	10.4	TP53, MME, CDKN2A, CDKN1A, CHEK2, CHEK1
16	response to hyperoxia	GO:055093	10.3	PDPN, NOS3, CAT, MMP9, CDKN1A, SFTPB
17	positive regulation of angiogenesis	GO:045766	10.3	KDR, CD34, MMP9, FLT1, FGF1, FGF2
18	protein autophosphorylation	GO:046777	10.3	PDGFRB, EGFR, EIF2AK3, SYK, CSF1R, SIK2
19	activation of pro-apoptotic gene products	GO:008633	10.2	TNFSF10, TNFRSF10B, CASP8, MAPK8, BAX, BCL2L11
20	phosphatidylinositol-mediated signaling	GO:048015	10.2	CSF1R, TYMS, PDGFRB, RPS6KB1, CASP9, IGF1R
21	positive regulation of MAPK cascade	GO:043410	10.2	PDGFA, PTPRC, IL6, FLT4, FLT1, CDH2
22	extracellular matrix disassembly	GO:022617	10.1	TIMP2, MMP9, MMP3, MMP2, MMP14, MMP10
23	induction of apoptosis	GO:006917	10.1	TNFRSF10A, TNFSF10, PYCARD, DAPK1, WT1, TGFB2
24	positive regulation of cell migration	GO:030335	10.1	PDGFA, PDGFRB, PDPN, EGFR, ABCC1, CSF1R
25	positive regulation of gene expression	GO:010628	10.1	NKX2-1, TGFB2, KRAS, PLAUR, MAPK8, MET
26	response to DNA damage stimulus	GO:006974	10.1	APC, MCM7, CASP3, CASP9, TP53, PPP1R15A
27	cell-cell adhesion	GO:016337	10.0	EGFR, PDPN, CTNNB1, TNXB, ITGA6, CDH1
28	cell proliferation	GO:008283	9.9	PDPN, EGFR, TGFA, TGFB2, SYK, STAT3
29	neuron apoptotic process	GO:051402	9.9	GAPDH, TP63, TP53, CASP3, BAX, BCL2
30	anti-apoptosis	GO:006916	9.9	ANXA5, IGF1R, HSP90B1, DAPK1, NOS3, NGFR
31	release of cytochrome c from mitochondria	GO:001836	9.9	TP53, CASP3, BAX, BCL2L1, BCL2, SOD2
32	induction of apoptosis by intracellular signals	GO:008629	9.8	CASP3, CASP8, CASP9, TP53, CYCS, MAPK8
33	positive regulation of MAP kinase activity	GO:043406	9.8	EGFR, EGF, KRAS, PDGFRB, PDGFA, FLT1
34	positive regulation of apoptotic process	GO:043065	9.8	TNFSF10, PYCARD, PTPRC, CTNNB1, PPP2R4, NOS3
35	negative regulation of cell growth	GO:030308	9.7	TGFB2, WT1, TP53, ESR2, GREM1, FGF2
36	response to hypoxia	GO:001666	9.6	CAT, ERCC2, NOS2, NOS3, TGFB2, PGF
37	negative regulation of cell proliferation	GO:008285	9.4	IFNB1, TP53, CTNNB1, NOS3, NF2, WT1
38	cell cycle arrest	GO:007050	9.3	APC, IFNG, TP53, PPP1R15A, TGFB2, IL8
39	positive regulation of transcription, DNA-dependent	GO:045893	9.3	TP53, TP63, SP1, CTNNB1, WT1, EGF
40	angiogenesis	GO:001525	9.2	PDGFA, EGF, TGFA, TGFB2, SYK, PGF
41	innate immune response	GO:045087	9.2	IFNB1, HSP90B1, CASP8, TXN, PYCARD, SYK
42	virus-host interaction	GO:019048	9.2	TP53, SP1, KRT7, KRT19, KPNA2, SYK
43	apoptotic process	GO:006915	9.0	SEMA3A, FGF2, GREM1, APC, MCL1, MAPK8
44	response to drug	GO:042493	8.9	NOS3, CTNNB1, IFNG, ENO2, RPS6KB1, ABCC1
45	negative regulation of apoptotic process	GO:043066	8.7	PIK3CG, BTC, VEGFA, KDR, BCL2, ERCC2
46	positive regulation of transcription from RNA polymerase II promoter	GO:045944	8.4	TP53, ERCC2, ESR1, IFNG, IFNB1, TP63
47	blood coagulation	GO:007596	8.3	KRAS, PDGFA, NOS3, NOS2, EGF, THBD
48	positive regulation of cell proliferation	GO:008284	8.2	CDK4, EGF, EGFR, HCLS1, TGFB2, CSF1R
49	cytokine-mediated signaling pathway	GO:019221	8.2	KRAS, KPNA2, STAT3, STAT1, CSF1R, CSF3
50	signal transduction	GO:007165	8.1	PLAUR, PLAU, PYCARD, TNXB, TNFSF10, TNFRSF10C

Molecular functions related to malignant mesothelioma according to GeneDecks:

(show all 15)

id	Name	GO ID	Score	Top Affiliating Genes
1	vascular endothelial growth factor-activated receptor activity	GO:005021	10.8	PDGFRB, NRP2, FLT4, FLT1, KDR
2	receptor activity	GO:004872	10.5	THBD, NGFR, PLXNA1, PLAUR, NRP2, TNFRSF10B
3	protein phosphatase binding	GO:019903	10.4	EIF2AK3, EGFR, CTNNB1, HSP90B1, FLT4, CDH1
4	protein kinase binding	GO:019901	10.3	CCNH, TP53, PTPRC, SYK, STAT3, GATA6
5	BH3 domain binding	GO:051434	10.1	MCL1, BAX, BCL2L1, BCL2
6	cyclin-dependent protein kinase inhibitor activity	GO:004861	10.1	CASP3, CDKN1C, CDKN2A, CDKN2B, CDKN1A
7	protein heterodimerization activity	GO:046982	9.7	MCL1, ENO2, TP53, PPP2R4, PDGFA, EGFR
8	transcription factor binding	GO:008134	9.6	STAT3, CTNNB1, SP1, TNFRSF10A, TP53, CD34
9	protein homodimerization activity	GO:042803	9.4	PYCARD, SP1, PPP2R4, NOS2, PDGFA, TKT
10	identical protein binding	GO:042802	9.1	IGF1R, CASP8, ESR1, TP53, TP63, EGFR
11	ATP binding	GO:005524	8.5	EGFR, PDGFRB, RPS6KB1, PPP2R4, DAPK1, TP53
12	enzyme binding	GO:019899	8.2	TP53, CTNNB1, PLAUR, EGFR, STAT1, CSF3
13	growth factor activity	GO:008083	8.1	IL6, PDGFA, EGF, TGFA, TGFB2, CSF3
14	cytokine activity	GO:005125	8.0	IFNA2, IFNB1, IFNG, TNFSF10, SPP1, TGFB2
15	protein binding	GO:005515	5.7	IGF1R, PYCARD, PTGER4, PTPRC, DAPK1, CYCS